RRP9 and prostate carcinoma: In our differential expression analysis, we found that CHCHD8, GNL3, PA2G4, and RRP9 have 27.0-, 38.6-, 12.8-, and 7.6-times higher expression in prostate cancer specimens in comparison to normal prostate tissue.